These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 17624602)

  • 1. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
    Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
    BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
    BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
    Ibrahim SS; Hafez EE; Hashishe MM
    J Exp Clin Cancer Res; 2010 Jun; 29(1):82. PubMed ID: 20579331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
    Arcand SL; Maugard CM; Ghadirian P; Robidoux A; Perret C; Zhang P; Fafard E; Mes-Masson AM; Foulkes WD; Provencher D; Narod SA; Tonin PN
    Breast Cancer Res Treat; 2008 Apr; 108(3):399-408. PubMed ID: 17541742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
    Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
    Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
    Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.